Protara Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
The following table provides information concerning Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Exchange Act) adopted, modified, or terminated in the three months ended March 31, 2026 by any director or any executive officer who is subject to the filing requirements of Section 16 of the Exchange Act. These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). These trading arrangements permit transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table below. These trading arrangements, identified as “Rule 10b5-1 Trading Arrangements”, only permit transactions upon expiration of the applicable mandatory cooling-off period under Rule 10b5-1.
| Name (Title) | Action Taken (Date of Action) | Nature of Trading Arrangement | Type of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Jesse Shefferman (President, Chief Executive Officer and Director) | Termination (March 17, 2026) | Sale | Rule 10b5-1 trading arrangement | March 25, 2026 – September 24, 2026 | 69,448 |
| Jesse Shefferman (President, Chief Executive Officer and Director) | Adoption (March 17, 2026) | Sale | Rule 10b5-1 trading arrangement | June 16, 2026 – April 28, 2028 | 754,054 |
No other director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended March 31, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.